We are seeking an exceptional senior leader with deep expertise in cancer genetics and genomics to join our team at the Regeneron Genetics Center. This Director-level role carries full accountability for the strategy and execution of cancer genetic product development — from aligning the vision with senior leadership and translating it into an actionable operational plan, through overseeing product development and setting the strategy for commercialization. The ideal candidate will bring a demonstrated track record of independence and impact, and will serve as the driving force for bringing cancer risk genomics into clinical and commercial reality.

In this role, a typical day might include the following:

•       Develop and deliver on cancer genetics testing opportunities, including germline testing partnerships, serving as the senior leader accountable for clinical cancer test development.

•       Define and own the end-to-end strategy for germline genetic cancer risk product development, translating organizational vision — aligned with senior leadership — into a clear, actionable operational roadmap with measurable milestones.

•       Develop and execute a comprehensive somatic genetics strategy for Regeneron’s oncology portfolio, identifying new opportunities for somatic profiling studies across tumor types and leveraging existing cancer genomics databases.

•       Lead and execute large-scale somatic cancer sequencing analyses, including whole-exome and whole-genome sequencing of tumor samples, RNA-seq, and integrative multi-OMICS studies to identify driver mutations, therapeutic vulnerabilities, and mechanisms of resistance.

•       Design and contribute to cancer molecular profiling and clinical correlation analyses that integrate germline and somatic mutational profiles with multi-modal transcriptomic, epigenetic, and proteomic data to support target discovery, indication selection, and patient stratification strategies.

•       Oversee all phases of product development for cancer risk genomics programs, ensuring scientific rigor, cross-functional alignment, and on-time delivery against strategic objectives.

•       Develop and execute the commercialization strategy for RGC cancer products, identifying market opportunities, go-to-market pathways, and partnerships that maximize clinical and commercial impact.

•       Collaborate with and lead a multidisciplinary genetics team consisting of human genetics scientists, bioinformaticians, and statistical geneticists to design, execute, and interpret genetics studies related to cancer risk, somatic evolution, mechanisms, and therapeutic outcomes.

This job might be for you if you:

•       Have a demonstrated ability to independently own and drive strategic programs in cancer risk genomics or oncology product development from conception through commercialization.

•       Bring innovative thinking and hands-on leadership to large-scale somatic cancer sequencing studies and integrative genomic analyses.

•       Have deep expertise in analyzing tumor sequencing data, including variant calling, mutational signature analysis, clonal evolution, copy number alterations, and structural variant detection.

•       Have experience in developing or contributing to germline diagnostic tests for cancer predisposition, risk assessment, or clinical decision-making.

•       Are a motivated senior leader with a desire to pursue genetic discovery in a fast-paced multidisciplinary environment and can effectively guide teams and align stakeholders toward strategic goals.

•       Have demonstrated experience in quantitative problem solving, statistical analyses, and translating somatic and germline genetic findings into clinical applications.

To be considered for this role, you must have an MD or MD/PhD with a strong background in quantitative biology applied to cancer genetics and genomics, and a proven ability to design and lead large-scale human cancer genomic programs delivering medically- and commercially-relevant outcomes.

A minimum of 12 years of research experience in cancer genetics, genomics, or oncology product development is required, with a commensurate level of independence, seniority, and demonstrated responsibility for program strategy and execution.